XML 45 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Net (Loss) Income Attributable to Common Stockholders Per Share
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Net (loss) income attributable to common stockholders per share Net (loss) income attributable to common stockholders per share
The following table sets forth the computation of the Company’s basic and diluted net (loss) income attributable to common stockholders per share for the years ended December 31, 2024, 2023, and 2022 (in thousands except share and per share data):
 Year Ended December 31,
 202420232022
Numerator
Net (loss) income$(6,020)$(12,148)$2,484 
Less: net loss (income) allocated to noncontrolling interests— — 92 
 
Net (loss) income attributable to common stockholders, basic and diluted$(6,020)$(12,148)$2,576 
      
Denominator     
Weighted-average common shares outstanding, attributable to common stockholders, basic130,611,330135,283,044134,510,831
Effect of employee stock plans— — 4,051,280
Weighted-average common shares outstanding, attributable to common stockholders, diluted130,611,330135,283,044138,562,111
      
Net (loss) income attributable to common stockholders per share, basic$(0.05)$(0.09)$0.02 
Net (loss) income attributable to common stockholders per share, diluted$(0.05)$(0.09)$0.02 
Stock-based compensation awards of approximately $7.2 million, $9.0 million, and $3.5 million shares for the years ended December 31, 2024, 2023, and 2022, respectively, were outstanding but were not included in the computation of diluted net income (loss) per share attributable to Cytek Biosciences, Inc. common stockholders, because the effect of including such shares would have been anti-dilutive in the periods presented.